Recombinant Calloselasma rhodostoma ancrod Protein (Yeast)，His

Ancrod, a Fredrickson and Sweeney-derived snake venom enzyme, has garnered attention in the field of biopharmaceutical research due to its unique mechanism of action as a defibrinating agent. This serine protease, originally extracted from the venom of the Malayan pit viper, is known for its ability to selectively cleave fibrinogen, resulting in the formation of fibrin degradation products and subsequent reduction of blood viscosity. The application of ancrod has been explored for various medical conditions, particularly in treating thrombotic disorders such as ischemic stroke and peripheral artery disease, as it offers a potentially safer alternative to traditional anticoagulants. Furthermore, its action on the coagulation pathways has led researchers to investigate its therapeutic potential in enhancing microcirculation and promoting tissue perfusion in ischemic tissues. Advances in recombinant DNA technology have enabled the production of recombinant ancrod proteins, which promise improved safety profiles and pharmacological properties. This research is pivotal, as it not only aims to optimize ancrod for clinical use but also enhances our understanding of coagulation mechanisms and their implications in various disease states. Overall, the study of recombinant ancrod serves as a significant contribution to the development of novel therapies that may mitigate the risks associated with thrombotic events while providing insights into targeted drug design.